Nosospecific features of redox processes in cystic fibrosis

A.E. Abaturov, A.P. Volosovets, A.E. Khudyakov

Abstract


The review of the literature presents current data on the characteristics of redox processes occurring in the respiratory tract in cystic fibrosis.

Keywords


diseases of the respiratory system; antioxidant system

References


Grasemann H, Al-Saleh S, Scott JA, et al. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am J Respir Crit Care Med. 2011 May 15;183(10):1363-8. doi: 10.1164/rccm.201012-1995OC.

Cantin AM, White TB, Cross CE, Forman HJ, Sokol RJ, Borowitz D. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic Biol Med. 2007 Jan 1;42(1):15-31. doi: 10.1016/j.freeradbiomed.2006.09.022.

Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med. 2012 Apr 5;18(4):509-19. doi: 10.1038/nm.2715.

Lorentzen D, Durairaj L, Pezzulo AA, et al. Concentration of the antibacterial precursor thiocyanate in cystic fibrosis airway secretions. Free Radic Biol Med. 2011 May 1;50(9):1144-50. doi: 10.1016/j.freeradbiomed.2011.02.013.

Corti A, Franzini M, Cianchetti S, et al. Contribution by polymorphonucleate granulocytes to elevated gamma-glutamyltransferase incystic fibrosis sputum. PLoS One. 2012;7(4):e34772. doi: 10.1371/journal.pone.0034772.

Cooper AJ, Pinto JT, Callery PS. Reversible and irreversible protein glutathionylation: biological and clinical aspects. Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):891-910. doi: 10.1517/17425255.2011.577738.

Darling KE, Evans TJ. Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis. Infect Immun. 2003 May;71(5):2341-9. PMID: 12704103.

Gotoh T, Mori M. Nitric oxide and endoplasmic reticulum stress. Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1439-46. doi: 10.1161/01.ATV.0000223900.67024.15.

Grasemann H, Ratjen F. Nitric oxide and L-arginine deficiency in cystic fibrosis. Curr Pharm Des. 2012;18(5):726-36. PMID: 22229575.

Haley CL, Colmer-Hamood JA, Hamood AN. Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium. BMC Microbiol. 2012 Aug 18;12:181. doi: 10.1186/1471-2180-12-181.

Hauber HP, Foley SC, Hamid Q. Mucin overproduction in chronic inflammatory lung disease. Can Respir J. 2006 Sep;13(6):327-35. PMID: 16983448.

Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989 Sep 8;245(4922):1066-73. PMID: 2475911.

Hartl D, Gaggar A, Bruscia E, et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros. 2012 Sep;11(5):363-82. doi: 10.1016/j.jcf.2012.07.003.

Lambiase A, Catania MR, Rossano F. Anaerobic bacteria infection in cystic fibrosis airway disease. New Microbiol. 2010 Jul;33(3):185-94. PMID: 20954436.

Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol. 2007 Jan;35(1):116-29. doi: 10.1080/01926230601060025.

Marozkina NV, Gaston B. Nitrogen balance in the ecosystem of the cystic fibrosis lung. Am J Respir Crit Care Med. 2011 May 15;183(10):1290-2. doi: 10.1164/rccm.201102-0288ED.

Velsor LW, Kariya C, Kachadourian R, Day BJ. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Respir Cell Mol Biol. 2006 Nov;35(5):579-86. doi: 10.1165/rcmb.2005-0473OC.

Ballatori N, Hammond CL, Cunningham JB, Krance SM, Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC andOATP/SLC21A families of membrane proteins. Toxicol Appl Pharmacol. 2005 May 1;204(3):238-55. doi: 10.1016/j.taap.2004.09.008.

Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med. 2007 Apr 15;175(8):816-21. doi: 10.1164/rccm.200607-1011OC.

Van Der Vliet A, Nguyen MN, Shigenaga MK, Eiserich JP, Marelich GP, Cross CE. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L537-46. PMID: 10956629.

Chapman AL, Morrissey BM, Vasu VT, et al. Myeloperoxidase-dependent oxidative metabolism of nitric oxide in the cystic fibrosis airway. J Cyst Fibros. 2010 Mar;9(2):84-92. doi: 10.1016/j.jcf.2009.10.001.

Gaston B, Ratjen F, Vaughan JW, et al. Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. Am J Respir Crit Care Med. 2002 Feb 1;165(3):387-90. doi: 10.1164/ajrccm.165.3.2106006.

Galli F, Battistoni A, Gambari R, et al; Working Group on Inflammation in Cystic Fibrosis. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta. 2012 May;1822(5):690-713. doi: 10.1016/j.bbadis.2011.12.012.

Lezo A, Biasi F, Massarenti P, Calabrese R, Poli G, Santini B, Bignamini E. Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels? J Cyst Fibros. 2013 Jan;12(1):35-41. doi: 10.1016/j.jcf.2012.06.002.

Ballatori N, Krance SM, Marchan R, Hammond CL. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol Aspects Med. 2009 Feb-Apr;30(1-2):13-28. doi: 10.1016/j.mam.2008.08.004.

Pongnimitprasert N, El-Benna J, Foglietti MJ, Gougerot-Pocidalo MA, Bernard M, Braut-Boucher F. Potential role of the "NADPH oxidases" (NOX/DUOX) family in cystic fibrosis. Ann Biol Clin (Paris). 2008 Nov-Dec;66(6):621-9. doi: 10.1684/abc.2008.0285.

Cacciatore I, Cornacchia C, Pinnen F, Mollica A, Di Stefano A. Prodrug approach for increasing cellular glutathione levels. Molecules. 2010 Mar 3;15(3):1242-64. doi: 10.3390/molecules15031242.

Dötsch J, Puls J, Klimek T, Rascher W. Reduction of neuronal and inducible nitric oxide synthase gene expression in patients with cystic fibrosis. Eur Arch Otorhinolaryngol. 2002 Apr;259(4):222-6. PMID: 12064512.

Rada B, Hably C, Meczner A, et al. Role of Nox2 in elimination of microorganisms. Semin Immunopathol. 2008 Jul;30(3):237-53. doi: 10.1007/s00281-008-0126-3.

Rottner M, Freyssinet JM, Martínez MC. Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir Res. 2009 Mar 13;10:23. doi: 10.1186/1465-9921-10-23.

Rubin BK. Mucus structure and properties in cystic fibrosis. Paediatr Respir Rev. 2007 Mar;8(1):4-7. doi: 10.1016/j.prrv.2007.02.004.

Rubin BK. Mucus, phlegm, and sputum in cystic fibrosis. Respir Care. 2009 Jun;54(6):726-32; discussion 732. PMID: 19467160.

Henke MO, John G, Rheineck C, Chillappagari S, Naehrlich L, Rubin BK. Serine proteases degrade airway mucins in cystic fibrosis. Infect Immun. 2011 Aug;79(8):3438-44. doi: 10.1128/IAI.01252-10.

Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol (1985). 1993 Dec;75(6):2419-24. PMID: 8125859.

Hayes E, Pohl K, McElvaney NG, Reeves EP. The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch Immunol Ther Exp (Warsz). 2011 Apr;59(2):97-112. doi: 10.1007/s00005-011-0113-6.

Conner GE, Wijkstrom-Frei C, Randell SH, Fernandez VE, Salathe M. The lactoperoxidase system links anion transport to host defense in cystic fibrosis. FEBS Lett. 2007 Jan 23;581(2):271-8. doi: 10.1016/j.febslet.2006.12.025.

González-Guerrico AM, Cafferata EG, Radrizzani M, et al. Tyrosine kinase c-Src constitutes a bridge between cystic fibrosis transmembrane regulator channel failure and MUC1 overexpression in cystic fibrosis. J Biol Chem. 2002 May 10;277(19):17239-47. doi: 10.1074/jbc.M112456200.




DOI: https://doi.org/10.22141/2224-0551.12.7.2017.116193

Copyright (c) 2017 Zdorov'ye Rebenka - Child`s Health

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта